ClinicalTrials.gg
CompletedNCT05423756Updated Aug 28, 2026Results posted

INSPIRE Trial for Skin and Soft Tissue Infections

An interventional study of Arm 1: Routine Care and Arm 2: INSPIRE Stewardship Bundle for Skin and Soft Tissue Infection in Skin and Soft Tissue (SST) Infection, sponsored by Harvard Pilgrim Health Care. Completed at 102 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by Harvard Pilgrim Health Care · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
118,562
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The INSPIRE Skin and Soft Tissue Infection trial is a cluster-randomized controlled trial of HCA Healthcare hospitals comparing routine empiric antibiotic stewardship practices with real-time, precision medicine computerized physician order entry (CPOE) smart prompts providing the probability that a non-critically ill adult admitted with skin and soft tissue infection is infected with a resistant pathogen.

Note: enrolled "subjects" represent 102 individual HCA Healthcare hospitals that have been randomized into 92 clusters. Hospitals were grouped into the same randomization cluster if they shared campuses or antibiotic stewardship staff.

02

Conditions studied

  • Skin and Soft Tissue (SST) Infection

Browse trials for

Keywords

  • SST
  • CPOE
  • Empiric Therapy
03

In context

Infections

2,097 studies on the registry are indexed under Infections; 361 are open to participants now.

This study's enrollment of 118,562 is above the median of 113 across 1,305 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Harvard Pilgrim Health Care is the lead sponsor of 35 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Facility Inclusion Criteria:

  1. HCA Healthcare hospitals admitting adults for skin and soft tissue infection
  2. Facility use of MEDITECH as their electronic health record system

Facility Exclusion Criteria:

-

Note: unit of randomization is the hospital, however the computerized physician order entry (CPOE) alert intervention will calculate risk estimates for adults age >=18 admitted to non-intensive care unit wards and who are ordered to receive extended-spectrum antibiotics for skin and soft tissue infection.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
118,562 participants (actual)

Study arms

  • Active comparator
    Arm 1: Routine Care

    Continuation of routine antibiotic stewardship strategies.

    Other: Arm 1: Routine Care

  • Active comparator
    Arm 2: INSPIRE Stewardship Bundle

    Use of computerized physician order entry (CPOE) smart prompts, clinician feedback, and activities to support CPOE adoption (including education and alignment of CPOE workflows) to guide empiric choice of antibiotics for skin/soft tissue infection in the first 3 days of hospitalization.

    Other: Arm 2: INSPIRE Stewardship Bundle for Skin and Soft Tissue Infection

Interventions

  • OtherArm 1: Routine Care

    Routine Antibiotic Stewardship Arm - Continuation of antibiotic stewardship activities in accordance with national standards.

  • OtherArm 2: INSPIRE Stewardship Bundle for Skin and Soft Tissue Infection

    Quality improvement intervention that includes (1) computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimates for having a skin/soft tissue infection due to a multidrug-resistant organism (MDRO) and recommends standard spectrum antibiotics for low risk patients in the first 3 days of hospitalization; (2) clinician feedback reports, and (3) activities to support CPOE adoption (including education and alignment of CPOE workflows). Other antibiotic stewardship activities to continue in accordance with national standards.

06

What researchers measure

Primary outcomes

  1. Extended-Spectrum Days of Antibacterial Therapy (ES-DOT) Per Empiric Day

    Days-of-Therapy is a standardized national measure for antibacterial use in hospitals that counts each different antibiotic administered on each calendar day as one day of therapy, regardless of doses given. Extended-spectrum days-of-therapy per empiric day is defined as the summed number of different extended-spectrum antibiotics received per patient each calendar day, beginning at admission. If an admission is less than 3 days, only the number of days the patient is admitted will contribute to the numerator and denominator. For example, 2 different extended-spectrum antibiotics administered at least once during each of the first 3 days would yield 6 days of extended-spectrum days-of-therapy.

    Time frame: First 3 calendar days of hospitalization for each patient during the 12-month baseline and 12-month intervention periods

Secondary outcomes

  1. Antipseudomonal Antibiotic Days Of Therapy (ES-DOT) Per Empiric Day

    Days-of-Therapy is a standardized national measure for antibacterial use in hospitals that counts each different antibiotic administered on each calendar day as one day of therapy, regardless of doses given. Antipseudomonal days-of-therapy per empiric day is defined as the summed number of different antipseudomonal antibiotics received per patient each calendar day, beginning at admission. If an admission is less than 3 days, only the number of days the patient is admitted will contribute to the numerator and denominator. For example, 2 different antipseudomonal antibiotics administered at least once during each of the first 3 days would yield 6 days of antipseudomonal days-of-therapy.

    Time frame: First 3 calendar days of hospitalization for each patient during the 12-month baseline and 12-month intervention periods

Other outcomes

  1. Intensive Care Unit (ICU) Transfer [Safety Outcome 1]

    Days from hospital admission until transfer to ICU, if that occurs. If it doesn't occur, the number of days is censored (capped) at the patient's hospital discharge or at the end of data collection. Almost all patients will be discharged before the end of trial data collection.

    Time frame: Duration of hospitalization for each patient during 12-month baseline and 12-month intervention periods

  2. Length-of-stay [Safety Outcome 2]

    Days from hospital admission until discharge. If the patient remains in the hospital at the end of the trial data collection, the number of days is censored (capped) at that time. Almost all patients will be discharged before the end of trial data collection.

    Time frame: Duration of hospitalization for each patient during 12-month baseline and 12-month intervention periods

  3. Extended-Spectrum Days of Therapy With Inpatient Extended-Spectrum (ES) Antibiotic Treatment After Empiric Period

    The number of different ES antibiotics received each day, on hospital days ≥4 and ≤14. Note: this outcome is intended for a secondary manuscript

    Time frame: 12 months

  4. Empiric and Total Antibiotic Costs

    Empiric and total antibiotic costs for skin and soft tissue infection during hospitalization. Note: this outcome is intended for a secondary manuscript.

    Time frame: 12 months

  5. Incidence of Hospital-Onset C. Difficile

    Hospital-onset C. difficile positive tests (specimen obtained) on hospital days ≥4 and ≤14. Note: this outcome is intended for a secondary manuscript.

    Time frame: 12 months

  6. Incidence of Hospital-Onset MDRO-Positive Cultures

    Newly-detected hospital-onset MDRO-positive cultures on hospital days ≥4 and ≤14. Includes total MDRO and specific MDRO subsets. Note: this outcome is intended for a secondary manuscript.

    Time frame: 12 months

07

Results

Posted Aug 26, 2025

Participant flow

92 out of 142 HCA Healthcare hospitals were recruited for this trial. There was a 12-month baseline period (January 1, 2019-December 31, 2019), 5-month phase-in (August 2, 2022-December 31, 2022), and 12-month intervention (January 1, 2023-December 31, 2023). Data from the phase-in period were excluded from all analyses (i.e., Baseline, Intervention, Outcome Measures, and Adverse Events).

Baseline (12 months)
Participant flow — Baseline (12 months)
MilestoneArm 1: Routine StewardshipArm 2: INSPIRE CPOE Bundle
Started2959528242
Completed2959528242
Not completed00
Intervention (12 months)
Participant flow — Intervention (12 months)
MilestoneArm 1: Routine StewardshipArm 2: INSPIRE CPOE Bundle
Started3133729388
Completed3133729388
Not completed00

Outcome measures

PrimaryExtended-Spectrum Days of Antibacterial Therapy (ES-DOT) Per Empiric Day

Days-of-Therapy is a standardized national measure for antibacterial use in hospitals that counts each different antibiotic administered on each calendar day as one day of therapy, regardless of doses given. Extended-spectrum days-of-therapy per empiric day is defined as the summed number of different extended-spectrum antibiotics received per patient each calendar day, beginning at admission. If an admission is less than 3 days, only the number of days the patient is admitted will contribute to the numerator and denominator. For example, 2 different extended-spectrum antibiotics administered at least once during each of the first 3 days would yield 6 days of extended-spectrum days-of-therapy.

Time frame:
First 3 calendar days of hospitalization for each patient during the 12-month baseline and 12-month intervention periods
Reported as:
Number · Extended-Spectrum Days-of-Therapy
Extended-Spectrum Days of Antibacterial Therapy (ES-DOT) Per Empiric Day
Extended-Spectrum Days-of-TherapyArm 1: Routine StewardshipArm 2: INSPIRE CPOE Bundle
Baseline (12 months)4330540156
Intervention (12 months)4392730287
SecondaryAntipseudomonal Antibiotic Days Of Therapy (ES-DOT) Per Empiric Day

Days-of-Therapy is a standardized national measure for antibacterial use in hospitals that counts each different antibiotic administered on each calendar day as one day of therapy, regardless of doses given. Antipseudomonal days-of-therapy per empiric day is defined as the summed number of different antipseudomonal antibiotics received per patient each calendar day, beginning at admission. If an admission is less than 3 days, only the number of days the patient is admitted will contribute to the numerator and denominator. For example, 2 different antipseudomonal antibiotics administered at least once during each of the first 3 days would yield 6 days of antipseudomonal days-of-therapy.

Time frame:
First 3 calendar days of hospitalization for each patient during the 12-month baseline and 12-month intervention periods
Reported as:
Number · Antipseudomonal Days-of-Therapy
Antipseudomonal Antibiotic Days Of Therapy (ES-DOT) Per Empiric Day
Antipseudomonal Days-of-TherapyArm 1: Routine StewardshipArm 2: INSPIRE CPOE Bundle
Baseline (12 months)4330538059
Intervention (12 months)4392730287
Other pre-specifiedIntensive Care Unit (ICU) Transfer [Safety Outcome 1]

Days from hospital admission until transfer to ICU, if that occurs. If it doesn't occur, the number of days is censored (capped) at the patient's hospital discharge or at the end of data collection. Almost all patients will be discharged before the end of trial data collection.

Time frame:
Duration of hospitalization for each patient during 12-month baseline and 12-month intervention periods
Reported as:
Mean · Days to event
Intensive Care Unit (ICU) Transfer [Safety Outcome 1]
Days to eventArm 1: Routine StewardshipArm 2: INSPIRE CPOE Bundle
Baseline (12 months)5.9 ± 2.86.1 ± 2.9
Intervention (12 months)6.3 ± 3.26.3 ± 3.1
Other pre-specifiedLength-of-stay [Safety Outcome 2]

Days from hospital admission until discharge. If the patient remains in the hospital at the end of the trial data collection, the number of days is censored (capped) at that time. Almost all patients will be discharged before the end of trial data collection.

Time frame:
Duration of hospitalization for each patient during 12-month baseline and 12-month intervention periods
Reported as:
Mean · Days to event
Length-of-stay [Safety Outcome 2]
Days to eventArm 1: Routine StewardshipArm 2: INSPIRE CPOE Bundle
Baseline (12 months)6.2 ± 3.76.1 ± 3.6
Intervention (12 months)6.5 ± 3.86.4 ± 3.8
Other pre-specifiedExtended-Spectrum Days of Therapy With Inpatient Extended-Spectrum (ES) Antibiotic Treatment After Empiric Period

The number of different ES antibiotics received each day, on hospital days ≥4 and ≤14. Note: this outcome is intended for a secondary manuscript

Time frame:
12 months

Results for this outcome have not been posted.

Other pre-specifiedEmpiric and Total Antibiotic Costs

Empiric and total antibiotic costs for skin and soft tissue infection during hospitalization. Note: this outcome is intended for a secondary manuscript.

Time frame:
12 months

Results for this outcome have not been posted.

Other pre-specifiedIncidence of Hospital-Onset C. Difficile

Hospital-onset C. difficile positive tests (specimen obtained) on hospital days ≥4 and ≤14. Note: this outcome is intended for a secondary manuscript.

Time frame:
12 months

Results for this outcome have not been posted.

Other pre-specifiedIncidence of Hospital-Onset MDRO-Positive Cultures

Newly-detected hospital-onset MDRO-positive cultures on hospital days ≥4 and ≤14. Includes total MDRO and specific MDRO subsets. Note: this outcome is intended for a secondary manuscript.

Time frame:
12 months

Results for this outcome have not been posted.

Adverse events

Collected over 12 months (baseline), 12 months (intervention). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1: Routine Stewardship0/60,932 (0%)0/60,932 (0%)0/60,932 (0%)
Arm 2: INSPIRE CPOE Bundle0/57,630 (0%)0/57,630 (0%)0/57,630 (0%)

Baseline characteristics

Overall number of participants reflects the total across baseline and intervention periods. 118,562 patients from 92 hospitals were randomized to a study group; Prior to the to start of the intervention period, 2 hospitals divested from the participating healthcare system, and thus were excluded from Arm 2: CPOE Bundle.

Age, Continuous
Age, Continuous(years)Arm 1: Routine StewardshipArm 2: INSPIRE CPOE BundleTotal
Baseline (12 months)58 ± 1858 ± 1858 ± 18
Intervention (12 months)59 ± 1858 ± 1759 ± 18
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Arm 1: Routine StewardshipArm 2: INSPIRE CPOE BundleTotal
Baseline (12 months) — Female130871237725464
Baseline (12 months) — Male163201571932039
Baseline (12 months) — Unknown188146334
Intervention (12 months) — Female133561701530371
Intervention (12 months) — Male179791237330352
Intervention (12 months) — Unknown202
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm 1: Routine StewardshipArm 2: INSPIRE CPOE BundleTotal
Baseline (12 months) — Black305236386690
Baseline (12 months) — White231532073043883
Baseline (12 months) — Other12466871933
Baseline (12 months) — Unknown214431875331
Intervention (12 months) — Black367239897661
Intervention (12 months) — White233852088544270
Intervention (12 months) — Other6853331018
Intervention (12 months) — Unknown359541817776
08

Study locations

102 sites
  • Riverside Community hospital
    Riverside, California 92501, United States
  • Regional Medical Center of San Jose
    San Jose, California 95116, United States
  • Good Samaritan Hospital
    San Jose, California 95124, United States
  • Los Robles Hospital & Medical Center
    Thousand Oaks, California 91360, United States
  • West Hills Hospital & Medical Center
    West Hills, California 91307, United States
  • The Medical Center of Aurora
    Aurora, Colorado 80012, United States
  • Swedish Medical Center
    Englewood, Colorado 80113, United States
  • Sky Ridge Medical Center
    Lone Tree, Colorado 80124, United States
  • North Suburban Medical Center
    Thornton, Colorado 80229, United States
  • Blake Medical Center
    Bradenton, Florida 34209, United States
  • Brandon Regional Hospital
    Brandon, Florida 33511, United States
  • Oak Hill Hospital
    Brooksville, Florida 34613, United States
  • Englewood Community Hospital
    Englewood, Florida 34223, United States
  • Fort Walton Beach Medical Center
    Fort Walton Beach, Florida 32547, United States
  • Lawnwood Regional Medical Center
    Ft. Pierce, Florida 34950, United States
  • Regional Medical Center Bayonet Point
    Hudson, Florida 34667, United States
  • Memorial Hospital Jacksonville
    Jacksonville, Florida 32216, United States
  • Lake City Medical Center
    Lake City, Florida 32055, United States
  • Largo Medical Center
    Largo, Florida 33770, United States
  • Northwest Medical Center
    Margate, Florida 33060, United States
  • Mercy Hospital
    Miami, Florida 33133, United States
  • Kendall Regional Medical Center
    Miami, Florida 33175, United States
  • Orange Park Medical Center
    Orange Park, Florida 32073, United States
  • Oviedo Medical Center
    Oviedo, Florida 32765, United States
  • Gulf Coast Regional Medical Center
    Panama City, Florida 32405, United States
  • Fawcett Memorial Hospital
    Port Charlotte, Florida 33952, United States
  • St. Lucie Medical Center
    Port Saint Lucie, Florida 34952, United States
  • Doctors Hospital of Sarasota
    Sarasota, Florida 34233, United States
  • Palms of Pasadena
    St. Petersburg, Florida 33707, United States
  • Northside Hospital
    St. Petersburg, Florida 33709, United States
  • St. Petersburg General Hospital
    St. Petersburg, Florida 33710, United States
  • South Bay Hospital
    Sun City Center, Florida 33573, United States
  • Capital Regional Medical Center
    Tallahassee, Florida 32308, United States
  • HCA Florida South Tampa Hospital
    Tampa, Florida 33609, United States
  • HCA Florida West Tampa Hospital
    Tampa, Florida 33615, United States
  • Medical Center of Trinity
    Trinity, Florida 34655, United States
  • JFK Medical Center - North Campus
    West Palm Beach, Florida 33407, United States
  • Fairview Park Hospital
    Dublin, Georgia 31040, United States
  • Eastern Idaho Regional Medical Center
    Idaho Falls, Idaho 83404, United States
  • Menorah Medical Center
    Overland Park, Kansas 66209, United States
  • Overland Park Regional Medical Center
    Overland Park, Kansas 66215, United States
  • Wesley Medical Center
    Wichita, Kansas 67214, United States
  • Wesley Woodlawn Hospital & ER
    Wichita, Kansas 67220, United States
  • TriStar Greenview Regional Hospital
    Bowling Green, Kentucky 42104, United States
  • Lakeview Regional Medical Center
    Covington, Louisiana 70433, United States
  • Tulane Medical Center
    New Orleans, Louisiana 70112, United States
  • Centerpoint Medical Center
    Independence, Missouri 64057, United States
  • Research Medical Center
    Kansas City, Missouri 64132, United States
  • Lee's Summit Medical Center
    Lee's Summit, Missouri 64063, United States
  • Sunrise Hospital and Medical Center
    Las Vegas, Nevada 89109, United States
  • Southern Hills Hospital & Medical Center
    Las Vegas, Nevada 89148, United States
  • Trident Medical Center
    Charleston, South Carolina 29406, United States
  • Grand Strand Medical Center
    Myrtle Beach, South Carolina 29572, United States
  • Parkridge Medical Center
    Chattanooga, Tennessee 37404, United States
  • Parkridge East Hospital
    Chattanooga, Tennessee 37412, United States
  • TriStar Horizon Medical Center
    Dickson, Tennessee 37055, United States
  • TriStar Hendersonville Medical Center
    Hendersonville, Tennessee 37075, United States
  • TriStar Centennial Medical Center
    Nashville, Tennessee 37203, United States
  • TriStar Southern Hills Medical Center
    Nashville, Tennessee 37211, United States
  • TriStar StoneCrest Medical Center
    Smyrna, Tennessee 37167, United States
  • Medical City Arlington
    Arlington, Texas 76015, United States
  • St. David's Medical Center
    Austin, Texas 78705, United States
  • St. David's North Austin Medical Center
    Austin, Texas 78758, United States
  • Valley Regional Medical Center
    Brownsville, Texas 78526, United States
  • HCA Houston Healthcare Conroe
    Conroe, Texas 77304, United States
  • Corpus Christi Medical Center - Doctors Regional
    Corpus Christi, Texas 78411, United States
  • Corpus Christi Medical Center - Bay Area
    Corpus Christi, Texas 78412, United States
  • Corpus Christi Medical Center - Heart Hospital
    Corpus Christi, Texas 78412, United States
  • Medical City Dallas
    Dallas, Texas 75230, United States
  • Medical City Denton
    Denton, Texas 76210, United States
  • Las Palmas Medical Center
    El Paso, Texas 79902, United States
  • Del Sol Medical Center
    El Paso, Texas 79925, United States
  • Medical City Fortworth
    Fort Worth, Texas 76104, United States
  • Medical City Alliance
    Fort Worth, Texas 76177, United States
  • Medical City Frisco
    Frisco, Texas 75034, United States
  • HCA Houston Healthcare West
    Houston, Texas 77082, United States
  • Medical City Las Colinas
    Irving, Texas 75039, United States
  • HCA Houston Healthcare Kingwood
    Kingwood, Texas 77339, United States
  • Medical City Lewisville
    Lewisville, Texas 75057, United States
  • Methodist Hospital | Metropolitan
    Live Oak, Texas 78212, United States
  • Methodist Hospital | Northeast
    Live Oak, Texas 78233, United States
  • Rio Grande Regional Hospital Main Campus
    McAllen, Texas 78503, United States
  • Medical City McKinney
    McKinney, Texas 75069, United States
  • Medical City North Hills
    North Richland Hills, Texas 76180, United States
  • HCA Houston Healthcare Southeast
    Pasadena, Texas 77504, United States
  • HCA Houston Healthcare Pearland
    Pearland, Texas 77584, United States
  • Medical City Plano
    Plano, Texas 75075, United States
  • St. David's Round Rock Medical Center
    Round Rock, Texas 78681, United States
  • Methodist Hospital | Texsan
    San Antonio, Texas 78201, United States
  • Methodist Hospital | Specialty and Trasnplant
    San Antonio, Texas 78229, United States
  • Methodist Hospital
    San Antonio, Texas 78229, United States
  • HCA Houston Healthcare Mainland
    Texas City, Texas 77591, United States
  • Medical City Weatherford
    Weatherford, Texas 76086, United States
  • HCA Houston Healthcare Clear Lake
    Webster, Texas 77598, United States
  • Ogden Regional Medical Center
    Ogden, Utah 84405, United States
  • LewisGale Hospital Montgomery
    Blacksburg, Virginia 24060, United States
  • John Randolph Medical Center
    Hopewell, Virginia 23860, United States
  • LewisGale Hospital Pulaski
    Pulaski, Virginia 24301, United States
  • Reston Hospital Center
    Reston, Virginia 20190, United States
  • Henrico Doctor's Hospital
    Richmond, Virginia 23220, United States

Showing the first 100 of 102 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gohil SK, Septimus E, Kleinman K, Varma N, Sands KE, Avery TR, Mauricio A, Sljivo S, Rahm R, Roemer K, Cooper WS, McLean LE, Nickolay NG, Poland RE, Weinstein RA, Fakhry SM, Guy J, Moody J, Coady MH, Smith KN, Meador B, Froman A, Eibensteiner K, Hayden MK, Kubiak DW, Burks C, Burgess LH, Calderwood MS, Perlin JB, Platt R, Huang SS. Improving Empiric Antibiotic Selection for Patients Hospitalized With Skin and Soft Tissue Infection: The INSPIRE 3 Skin and Soft Tissue Randomized Clinical Trial. JAMA Intern Med. 2025 Jun 1;185(6):680-691. doi: 10.1001/jamainternmed.2025.0887. PubMed 40208610 ↗
  • Gohil SK, Avery TR, Kleinman K, Septimus E, Mauricio A, Sands KE, Varma N, Sljivo S, Roemer K, Cooper WS, Poland RE, Weinstein RA, Fakhry SM, Guy J, Moody J, Coady MH, Smith-Sells KN, Hayden MK, Kubiak DW, Burks C, Platt R, Huang SS, Baker MA. Improving Empiric Antibiotic Selection for Patients With Cancer Hospitalized With Infection: Secondary Analysis of the INSPIRE Cluster Randomized Trials. JAMA Netw Open. 2026 Jun 1;9(6):e2616611. doi: 10.1001/jamanetworkopen.2026.16611. PubMed 42268612 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in May 2024, 16 months.

Results were first posted in Aug 2025, 1 year 3 months after primary completion.

Of 276 non-industry interventional studies with no phase under Infections, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 51. This study's 16 months is below that.

Counting every sponsor, half of 308 studies reached it within 24 months; a quarter within 9 and three quarters within 48.

Infections covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2022
First posted
Jun 21, 2022
StartActual
Jan 1, 2023
Primary completionActual
May 9, 2024
CompletionActual
May 9, 2024
Results first posted
Aug 26, 2025
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05423756
Lead sponsor
Harvard Pilgrim Health Care
Collaborators
Hospital Corporation of America, University of California, Irvine, University of Massachusetts, Amherst, Brigham and Women's Hospital, Rush University
Responsible party
Richard Platt (MD, MSc, Professor and Chair, Department of Population Medicine, Harvard Pilgrim Health Care) — Principal investigator
First posted
Jun 21, 2022
Start date
Jan 1, 2023
Primary completion
May 9, 2024
Completion
May 9, 2024
Results posted
Aug 26, 2025
Last update
Aug 28, 2026

Study contacts

Shruti Gohil, MD, MPH
study director · UC Irvine Division of Infectious Diseases
Susan Huang, MD, MPH
principal investigator · UC Irvine Division of Infectious Diseases
Richard Platt, MD, MS
principal investigator · Harvard Pilgrim Health Care Institute/Harvard Medical School

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion